ADVERTISEMENT
Pricing Strategies
A US class action suit alleges that a settlement between Teva and Novo Nordisk illegally delayed generic Victoza for 16 months, kept prices high and transferred an estimated $903m in value to Teva.
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
BMS tells Scrip it will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Brazilian authorities say that some pharmaceutical companies exploit court cases brought by patients to secure drug access to achieve higher prices.
In a busy month for triple-digit percentage average price rises for generics in the UK, repaglinide led the pack in December.
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
The US ranibizumab market has seen more than its fair share of ups and downs, with the latest developments vastly reducing biosimilar penetration and allowing Lucentis to recapture around 90% of the market. Generics Bulletin looks at the reasons why.
The health technology assessment institute said its recommendation for the multiple sclerosis drugs, Tysabri and Tyruko, highlighted its continued efforts to drive the adoption of biosimilars across the National Health Service.
In today’s rapidly shifting US healthcare landscape, direct-to-consumer strategies, once used mainly by pharma companies, are now drawing strong interest from payers.
Industry veterans put themselves in Novo’s shoes, suggesting pricing manoeuvres and tactical measures to blunt competition in India post semaglutide’s LOE in 2026. There’s also court action to watch.
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.